levels below 3.0 mEq/L require urgent intervention due to cardiac arrhythmia risk
Comparisons With Other Diabetes Therapies Putting GLP1s in context with other antidiabetic agents offers additional insights: Thiazolidinediones (TZDs) are associated with increased fracture risk, especially in women SGLT2 inhibitors have raised concerns in some trials, particularly canagliflozin DPP-4 inhibitors appear largely neutral regarding skeletal effects Against this backdrop, GLP1s may have a neutral or possibly safer profile, though the data are not conclusive
Metabolic factors also matter: patients with insulin resistance, type 2 diabetes, or BMI-related metabolic syndrome respond differently to dual mechanisms
July 2025 As of July 1, 2025, there are 1,997 lawsuits pending in the GLP-1RA multidistrict litigation
Some patients worry: "If I lose weight and my BMI drops below 30, will they stop covering Wegovy?" Generally, insurers don't discontinue coverage just because you've lost weight that would defeat the purpose
Healthy B-12 levels support cell turnover and growth, which can lead to stronger nails, healthier hair, and more balanced skin over time